Compare Altria Group Inc (MO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Revvity Inc — how do they compare? Altria Group Inc trades at $67.94 (market cap $113.83B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Altria Group Inc is far larger — about 8× Revvity Inc's market cap, and Altria Group Inc pays the higher dividend (6.51%). Which is the better fit depends on your goals.
| MO | RVTY | |
|---|---|---|
Market Cap | $113.83B | $14.18B |
Sector | Consumer Staples | Technology |
52-Week High | $74.92 | $130.94 |
52-Week Low | $54.72 | $82.26 |
Enterprise Value | $136.04B | $16.50B |
Dividend Yield | 6.51% | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $68.18, down 1.02% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock offers a high dividend yield of 6.45% following its 61st annual increase. Recent earnings show mixed quarterly results, with Q1 2026 beating expectations but Q2 2026 missing. Revenue remains stable around $20.1 billion (2025), with strong profitability margins, though net income declined to $6.95 billion in 2025 from $11.3 billion in 2024. Analyst consensus is bullish with a $68.50 price target.
MO presents a value opportunity with a low P/E of 14.35 and robust cash flows supporting dividends, but faces risks from regulatory lawsuits, declining cigarette volumes, and high debt levels. The stock's appeal hinges on dividend sustainability amid secular challenges in the tobacco industry.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
